Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Ashlins signs exclusive license and supply agreement with Lee’s Pharm for interferon alpha-2b

Ashlins Pharmaceuticals, through its subsidiary Ashlins Ocular Pharmaceuticals, granted exclusive development and commercialization rights for interferon alpha-2b from Lee’s Pharmaceutical outside mainland China, Hong Kong, Macau and Taiwan. Lee’s Pharm will supply the active ingredient and may receive upfront payments and up to $31 million in milestone payments, provided conditions are met. Ashlins plans to develop and commercialize the clinically validated asset primarily in the United States. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, LEE S PHARMACEUTIC.HD-,05 has already paid €0.0065 in dividends. The last payout was in October.

Financials

In the last quarter, LEE S PHARMACEUTIC.HD-,05 had revenue of €88.99M and net profit of €10.61M

(EUR)	June 2026	YoY
Revenue	88.99M	137.01%
Gross profit	49.99M	156.92%
Net profit	10.61M	192.37%
EBITDA	2.64M	64.77%

Fundamentals

Metric	Value
Market capitalization	€71.19M
Number of shares	588.84M
52-week high/low	€0.23 - €0.11
Dividend yield	5.42%
Dividends TTM	€0.0065
Beta	0.57
P/E ratio	3.75
PEG ratio	0.06
P/B ratio	0.29
P/S ratio	0.32

Company profile

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Aloxi and Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renaltransplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution to treat primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.